COMPANY

Circumvent Pharmaceuticals

Keywords: neurology neurodegenerative disease neuronal ceroid lipofuscinosis 3

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.22M (SBIR Phase II 5R44NS120360-04, continuation, notice Aug 3, 2026). NIH RePORTER 5R44NS120360-04 (Aug 3, 2026)
Evidence (1 event)
- Aug 3, 2026 · NIH RePORTER 5R44NS120360-04
  Organization: CIRCUMVENT PHARMACEUTICALS, INC.; City/State: PORTLAND, CA; Project number: 5R44NS120360-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1219273; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a Therapeutic Agent for Treating CLN1 Batten Disease; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 3, 2026 Grant Government grant — SBIR: $1.22M (annual award, as published), announced Aug 3, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 22, 2025 Grant Government grant — SBIR: $1.24M (annual award, as published), announced Aug 22, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Last 2 years.

Aug 3, 2026 Government grant — SBIR: $1.22M (annual award, as published), announced Aug 3, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 22, 2025 Government grant — SBIR: $1.24M (annual award, as published), announced Aug 22, 2025. Agency: NIH/NINDS. Source: government award database. source ↗